BioSpace News Archive

Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock.

Blue Biotechnology Trends That Will Disrupt the Market: Derivation of Active Ingredients from Aquatic Organisms

When the world’s largest radiologic science association wanted to spread the word about the dedicated health care professionals who perform medical imaging and radiation therapy procedures, it didn’t employ national television or digital billboards. It turned to public libraries.

Sanifit, a clinical-stage biopharmaceutical company focused on treatments for progressive vascular calcification disorders, today announced that the international Phase 2b CaLIPSO study of SNF472 in patients with end stage kidney disease (ESKD) on hemodialysis has met its primary endpoint.

Conference Call Scheduled for Tuesday, November 5 at 8:30 a.m. Eastern Time

Intensity Therapeutics, Inc. announced that the first patient has been dosed with a combination of INT230-6, the Company’s lead investigational product, and Keytruda®, Merck’s anti-PD-1 therapy.

Reports quarterly revenue of $69.4 million, representing 40% reported growth and 28% organic growth year-over-year

Key data presentations at ASH, including data from the pivotal TRANSCEND™ NHL-001 trial with liso-cel in R/R large B-cell NHL

Unique product platform combines antibacterial capabilities within a high-performance hemostat

Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2019 financial results and provide a corporate update before market open on Thursday, November 7, 2019.